Radiant Pharmaceutical Ltd.
Efodio is indicated for Gastritis, Lactation, Migraine, Nausea and vomiting, Gastroparesis, Non ulcer dyspepsia
Precautions and warnings
Drowsiness, extrapyramidal reactions, galactorrhoea, gynaecomastia; constipation or diarrhoea, lassitude, decreased libido, skin rash, itch.
Potentially Fatal: Convulsions, arrhythmias and cardiac arrest, dysrrhythmias in patients with CV disease or hypokalaemia, patients on cancer chemotherapy. Seizures; hypertensive crisis in patients with phaeochromocytoma.
May antagonise the hypoprolactinaemic effect of bromocriptine. May antagonise the prokinetic effect w/ opioid analgesics and antimuscarinics.
Potentially Fatal: Potent CYP3A4 inhibitors (e.g. ketoconazole, erythromycin or ritonavir) may increase serum domperidone levels and subsequently increasing the risk of QT prolongation.
Hypersensitivity. GI haemorrhage, obstruction and perforation, patients with prolactin releasing pituitary hormone, chronic admin or routine prophylaxis of postoperative nausea and vomiting.
Mode of actions
Domperidone is a peripheral dopamine-receptor blocker. It increases oesophageal peristalsis, enhances gastroduodenal coordination and lowers oesophageal sphincter pressure, gastric motility and peristalsis, thus facilitating gastric emptying and decreasing small bowel transit time.
Dosage & Administration
Adults : 10 - 20 mg every 4 - 8 hours daily
Children : 0.2 - 0.4 mg/kg every 4 - 8 hours daily.
Nausea and vomiting 10-20 mg 4-8 hrly. Max: 80 mg/day.
Non ulcer dyspepsia 10-20 mg 3 times/day and at night.
Migraine 20 mg 4 hrly. Max: 4 doses/24 hr.
Rectal: Nausea and vomiting 60 mg twice daily.
Pregnancy & Lactation
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks